New York, November 20, 2017 – Octane’s Cocoon automated bioreactor is this year’s recipient of the Silver prize in the Health category of the Spark Design Awards, an 11-year-old competition that recognizes modern designs which innovate, change the game and, in some way, help humanity or the environment.
Cocoon certainly ticks off all these boxes. This breakthrough bioreactor technology automates the manufacturing of patient-specific cell and tissue therapies, taking personalized regenerative medicine to the next level.
“We at Octane are so proud of Cocoon and we are grateful to the jurors at Spark for recognizing Cocoon’s ability to transform regenerative medicine,” says Octane CEO Tim Smith.
Cell therapy for personalized medicine has demonstrated great potential for fighting diseases such as cancer. But current manual processes for producing patient-specific cells are time-consuming, inefficient and potentially prone to contamination.
With Cocoon, these manual processes are automated and accelerated to produce breakthrough patient-specific treatments that are economical, safe and commercially scalable.
“Fundamentally, the Cocoon system optimizes the biology of growing healthy cells and tissues for re-implantation into the patient,” says Smith. “It truly is a game changer in regenerative medicine.”
For press inquiries please contact Renee Thibodeau.
The Spark mission is to promote better living through better design. Spark Awards are tri-annual affairs, with different design categories judged in June and November in San Francisco and December in Hong Kong. Both design professionals and students actively participate throughout the year. Learn more about the Spark organization and mission at the landing page at www.sparkawards.com
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
December 15, 2020
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
March 18, 2020
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...
October 29, 2018